Apellis Pharmaceuticals shares are trading higher after Wells Fargo upgraded the stock from Equal-Weight to Overweight and raised its price target from $34 to $64.
Portfolio Pulse from Benzinga Newsdesk
Wells Fargo has upgraded Apellis Pharmaceuticals from Equal-Weight to Overweight and raised its price target from $34 to $64. This has resulted in Apellis Pharmaceuticals' shares trading higher.
September 15, 2023 | 2:57 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals' stock has been upgraded by Wells Fargo, leading to a rise in its share price. The price target has also been increased from $34 to $64.
The upgrade from Wells Fargo is a positive signal for investors, indicating a bullish outlook for the stock. This, coupled with the raised price target, has led to an increase in the stock's price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100